The present invention provides a vaccine composition for treating or preventing cancer expressing VASH2, containing a peptide including an amino acid sequence represented by SEQ ID NO: 4.

The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers and their use in treating or preventing coronavirus infections and Acute Respiratory Distress Syndrome

The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers and their use in treating or preventing coronavirus infections and Acute Respiratory Distress Syndrome

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.

The invention provides a pharmaceutical composition and methods for the treatment of a respiratory disease that results from a viral infection. The pharmaceutical composition can include a peptide that interferes with the Src family kinase-Androgen receptor interaction (i.e., an “SA inhibitor”). The composition can also include Niacin or a Niacin derivative and/or a DNase I or fragment or derivative. The pharmaceutical composition can prevent the development of Acute Respiratory Distress Syndrome (ARDS) associated with Corona vims infection and allow the host adaptive immune response to overcome the infection.

The invention provides a pharmaceutical composition and methods for the treatment of a respiratory disease that results from a viral infection. The pharmaceutical composition can include a peptide that interferes with the Src family kinase-Androgen receptor interaction (i.e., an “SA inhibitor”). The composition can also include Niacin or a Niacin derivative and/or a DNase I or fragment or derivative. The pharmaceutical composition can prevent the development of Acute Respiratory Distress Syndrome (ARDS) associated with Corona vims infection and allow the host adaptive immune response to overcome the infection.

A synergistic non-toxic formulation for management of respiratory pathogens including coronaviruses and the process of preparing the synergistic formulation. The effective, non-toxic composition comprises of biological peptides including calcium chelating peptide and zinc chelating peptides, protease inhibitor such as 9-Arginine-peptide and inhibitor of viral replication enzyme such as vitamin B12 to reduce the presence of respiratory viruses including coronaviruses. The formulation is a cocktail of ingredients having a synergistic effect which is capable of being administered through various means including by way of inhalation, as nasal spray or an oral pump or via nebulizer to inhibit the entry and replication of respiratory pathogens. The combination of the formulation is such that it can be customized for a number of viral infections. The formulation is economical, self-administrable and effective even in low doses.

A synergistic non-toxic formulation for management of respiratory pathogens including coronaviruses and the process of preparing the synergistic formulation. The effective, non-toxic composition comprises of biological peptides including calcium chelating peptide and zinc chelating peptides, protease inhibitor such as 9-Arginine-peptide and inhibitor of viral replication enzyme such as vitamin B12 to reduce the presence of respiratory viruses including coronaviruses. The formulation is a cocktail of ingredients having a synergistic effect which is capable of being administered through various means including by way of inhalation, as nasal spray or an oral pump or via nebulizer to inhibit the entry and replication of respiratory pathogens. The combination of the formulation is such that it can be customized for a number of viral infections. The formulation is economical, self-administrable and effective even in low doses.